With several potent biaryl families of TTR inhibitors available, the current drug discovery initiatives have targeted diverse chemotypes, focusing on various amyloidogenic conditions, including TTR-mutant amyloidosis, sparing off-target anti-inflammatory activity, and reducing the toxic effects of long-term NSAID administration. This evidence concerns the gene TTR and amyloidosis.